Symbols / DYAI
DYAI Chart
About
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and large-scale manufacture of cost-effective enzymes, proteins, metabolites, and other biologic products for life sciences, food and nutrition, and bioindustrial applications. In addition, it develops DYAI-100, a C1-SARS-CoV-2 recombinant protein RBD vaccine candidate and first C1, which is in phase 1 clinical trial to produce protein tested in humans. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; joint development agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 30.36M |
| Enterprise Value | 25.73M | Income | -7.35M | Sales | 3.34M |
| Book/sh | 0.07 | Cash/sh | 0.25 | Dividend Yield | — |
| Payout | 0.00% | Employees | 6 | IPO | — |
| P/E | — | Forward P/E | -2.62 | PEG | — |
| P/S | 9.08 | P/B | 11.65 | P/C | — |
| EV/EBITDA | — | EV/Sales | 7.70 | Quick Ratio | 2.44 |
| Current Ratio | 2.85 | Debt/Eq | 194.16 | LT Debt/Eq | — |
| EPS (ttm) | -0.22 | EPS next Y | -0.32 | EPS Growth | — |
| Revenue Growth | -40.50% | Earnings | 2026-03-25 | ROA | -39.72% |
| ROE | -244.15% | ROIC | — | Gross Margin | 31.54% |
| Oper. Margin | -164.23% | Profit Margin | -219.86% | Shs Outstand | 36.19M |
| Shs Float | 30.20M | Short Float | 0.50% | Short Ratio | 2.78 |
| Short Interest | — | 52W High | 1.57 | 52W Low | 0.71 |
| Beta | 1.27 | Avg Volume | 208.88K | Volume | 9.00K |
| Target Price | $7.00 | Recom | None | Prev Close | $0.82 |
| Price | $0.84 | Change | 2.57% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.00
Mean price target
2. Current target
$0.84
Latest analyst target
3. DCF / Fair value
$-1.77
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.84
Low
$5.00
High
$9.00
Mean
$7.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-07-08 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2023-11-13 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2023-05-24 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2023-02-03 | reit | HC Wainwright & Co. | — → Buy | $6 |
| 2022-07-18 | down | Dawson James | Buy → Neutral | — |
| 2022-04-05 | main | HC Wainwright & Co. | — → Buy | $6 |
| 2021-12-17 | init | HC Wainwright & Co. | — → Buy | $7 |
- Craig Hallum Bullish on Dyadic International, Inc. (DYAI) With $5 Target - Yahoo Finance Sun, 21 Sep 2025 07
- Why DYAI stock appeals to analysts - July 2025 Sector Moves & Free Fast Gain Swing Trade Alerts - mfd.ru Fri, 20 Feb 2026 22
- Dyadic Applied BioSolutions and BRIG BIO Announce Partnership for Development of Recombinant Alpha-Lactalbumin - Quiver Quantitative Mon, 01 Dec 2025 08
- Dyadic International receives Nasdaq notice for minimum bid price deficiency - Investing.com Wed, 23 Jul 2025 07
- Health Check: How Prudently Does Dyadic International (NASDAQ:DYAI) Use Debt? - simplywall.st hu, 24 Jul 2025 07
- Dyadic International’s Tiny Stock, Big Volatility: Can DYAI’s Latest Rally Really Last? - AD HOC NEWS Sun, 04 Jan 2026 08
- Dyadic Applied BioSolutions Enters Agreement with Opes Diagnostics to Launch Recombinant Protein Products for Serum-Free Cell Culture Media - Quiver Quantitative Mon, 15 Dec 2025 08
- Craig-Hallum Maintains Dyadic(DYAI.US) With Buy Rating - 富途牛牛 ue, 07 Oct 2025 07
- Healthcare stocks that could be poised for a rebound - Seeking Alpha Fri, 09 May 2025 07
- Dyadic Applied BioSolutions and Proliant Health Launch AlbuFreeâ„¢ DX, a Recombinant Human Albumin Product - Quiver Quantitative ue, 17 Feb 2026 12
- Playing the Bird Flu Trade: CVAC BIXT NNVC GOVX DYAI NVAX - Insider Financial hu, 23 May 2024 07
- Dyadic International Completes Strategic Pivot to Commercial Focus, Reports Q3 2025 Financial Results and Milestones - Quiver Quantitative Wed, 12 Nov 2025 08
- Dyadic International, Inc. to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13 - Quiver Quantitative ue, 05 Aug 2025 07
- Dyadic International Receives $3 Million Grant from Gates Foundation for Monoclonal Antibody Development Targeting RSV and Malaria - Quiver Quantitative hu, 21 Nov 2024 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 102609 | — | — | Stock Award(Grant) at price 0.00 per share. | EMALFARB MARK A | Chief Executive Officer | — | 2026-01-02 00:00:00 | D |
| 1 | 29158 | — | — | Stock Award(Grant) at price 0.00 per share. | RAWSON PING WANG | Chief Financial Officer | — | 2026-01-02 00:00:00 | D |
| 2 | 18064 | — | — | Stock Award(Grant) at price 0.00 per share. | TCHELET RONEN | Officer | — | 2026-01-02 00:00:00 | D |
| 3 | 36418 | — | — | Stock Award(Grant) at price 0.00 per share. | HAZELTON JOSEPH P | President | — | 2026-01-02 00:00:00 | D |
| 4 | 21552 | nan | — | — | KAYE JACK | Director | — | 2026-01-02 00:00:00 | D |
| 5 | 21552 | nan | — | — | LUCY PATRICK K | Director | — | 2026-01-02 00:00:00 | D |
| 6 | 21552 | nan | — | — | HERBST SETH J. M.D. | Director | — | 2026-01-02 00:00:00 | D |
| 7 | 26000 | 24700.0 | — | Purchase at price 0.95 per share. | HAZELTON JOSEPH P | President | — | 2025-08-01 00:00:00 | D |
| 8 | 10776 | nan | — | — | TARNOK MICHAEL P | Director | — | 2025-06-20 00:00:00 | D |
| 9 | 10776 | nan | — | — | BOSE ARINDAM | Director | — | 2025-06-20 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -5.42M | -7.77M | -10.07M | -16.14M |
| TotalUnusualItems | 40.08K | 979.17K | -49.92K | 1.51M |
| TotalUnusualItemsExcludingGoodwill | 40.08K | 979.17K | -49.92K | 1.51M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -5.81M | -6.80M | -9.74M | -13.07M |
| ReconciledCostOfRevenue | 1.19M | 1.98M | 2.12M | 1.94M |
| EBITDA | -5.38M | -6.80M | -10.12M | -14.63M |
| EBIT | -5.38M | -6.80M | -10.12M | -14.63M |
| NetInterestIncome | 29.02K | 416.69K | 180.42K | 51.70K |
| InterestExpense | 427.97K | 0.00 | ||
| InterestIncome | 456.99K | 416.69K | 180.42K | 51.70K |
| NormalizedIncome | -5.85M | -7.77M | -9.69M | -14.58M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -5.81M | -6.80M | -9.74M | -13.07M |
| TotalExpenses | 9.37M | 11.09M | 13.05M | 17.03M |
| TotalOperatingIncomeAsReported | -5.90M | -8.23M | -10.17M | -14.73M |
| DilutedAverageShares | 29.32M | 28.80M | 28.36M | 27.84M |
| BasicAverageShares | 29.32M | 28.80M | 28.36M | 27.84M |
| DilutedEPS | -0.20 | -0.24 | -0.34 | -0.47 |
| BasicEPS | -0.20 | -0.24 | -0.34 | -0.47 |
| DilutedNIAvailtoComStockholders | -5.81M | -6.80M | -9.74M | -13.07M |
| NetIncomeCommonStockholders | -5.81M | -6.80M | -9.74M | -13.07M |
| NetIncome | -5.81M | -6.80M | -9.74M | -13.07M |
| NetIncomeIncludingNoncontrollingInterests | -5.81M | -6.80M | -9.74M | -13.07M |
| NetIncomeContinuousOperations | -5.81M | -6.80M | -9.74M | -13.07M |
| TaxProvision | 0.00 | |||
| PretaxIncome | -5.81M | -6.80M | -9.74M | -13.07M |
| OtherIncomeExpense | 40.08K | 979.17K | 200.08K | 1.51M |
| OtherNonOperatingIncomeExpenses | 250.00K | |||
| SpecialIncomeCharges | 62.64K | 1.02M | 0.00 | |
| GainOnSaleOfBusiness | 62.64K | 1.02M | 0.00 | |
| GainOnSaleOfSecurity | -22.56K | -38.42K | -49.92K | 1.51M |
| NetNonOperatingInterestIncomeExpense | 29.02K | 416.69K | 180.42K | 51.70K |
| InterestExpenseNonOperating | 427.97K | 0.00 | ||
| InterestIncomeNonOperating | 456.99K | 416.69K | 180.42K | 51.70K |
| OperatingIncome | -5.88M | -8.19M | -10.12M | -14.63M |
| OperatingExpense | 8.18M | 9.11M | 10.92M | 15.09M |
| ResearchAndDevelopment | 2.04M | 3.30M | 4.50M | 8.39M |
| SellingGeneralAndAdministration | 6.13M | 5.82M | 6.42M | 6.70M |
| GeneralAndAdministrativeExpense | 6.13M | 5.82M | 6.42M | 6.70M |
| OtherGandA | 6.13M | 5.82M | 6.42M | 6.70M |
| GrossProfit | 2.30M | 922.96K | 807.11K | 459.39K |
| CostOfRevenue | 1.19M | 1.98M | 2.12M | 1.94M |
| TotalRevenue | 3.50M | 2.90M | 2.93M | 2.40M |
| OperatingRevenue | 3.50M | 2.90M | 2.93M | 2.40M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 12.25M | 12.25M | 12.25M | 12.25M |
| OrdinarySharesNumber | 29.84M | 28.81M | 28.56M | 28.23M |
| ShareIssued | 42.09M | 41.06M | 40.82M | 40.48M |
| TotalDebt | 5.07M | 136.93K | 0.00 | |
| TangibleBookValue | 2.47M | 5.88M | 11.09M | 18.39M |
| InvestedCapital | 7.45M | 5.88M | 11.09M | 18.39M |
| WorkingCapital | 7.38M | 5.82M | 10.97M | 18.45M |
| NetTangibleAssets | 2.47M | 5.88M | 11.09M | 18.39M |
| CapitalLeaseObligations | 88.87K | 136.93K | 0.00 | |
| CommonStockEquity | 2.47M | 5.88M | 11.09M | 18.39M |
| TotalCapitalization | 7.45M | 5.88M | 11.09M | 18.39M |
| TotalEquityGrossMinorityInterest | 2.47M | 5.88M | 11.09M | 18.39M |
| StockholdersEquity | 2.47M | 5.88M | 11.09M | 18.39M |
| TreasuryStock | 18.93M | 18.93M | 18.93M | 18.93M |
| RetainedEarnings | -86.09M | -80.28M | -73.48M | -63.75M |
| AdditionalPaidInCapital | 107.44M | 105.04M | 103.46M | 101.03M |
| CapitalStock | 42.09K | 41.06K | 40.82K | 40.48K |
| CommonStock | 42.09K | 41.06K | 40.82K | 40.48K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 7.46M | 2.34M | 2.63M | 2.91M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 5.01M | 88.87K | 176.47K | 352.94K |
| NonCurrentDeferredLiabilities | 0.00 | 176.47K | 352.94K | |
| NonCurrentDeferredRevenue | 0.00 | 176.47K | 352.94K | |
| LongTermDebtAndCapitalLeaseObligation | 5.01M | 88.87K | 0.00 | |
| LongTermCapitalLeaseObligation | 34.62K | 88.87K | 0.00 | |
| LongTermDebt | 4.98M | |||
| CurrentLiabilities | 2.45M | 2.25M | 2.45M | 2.56M |
| CurrentDeferredLiabilities | 833.81K | 490.11K | 217.21K | 298.21K |
| CurrentDeferredRevenue | 0.00 | 176.47K | 147.06K | |
| CurrentDebtAndCapitalLeaseObligation | 54.25K | 48.06K | ||
| CurrentCapitalLeaseObligation | 54.25K | 48.06K | 0.00 | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 580.26K | 405.76K | ||
| PayablesAndAccruedExpenses | 1.56M | 1.71M | 2.23M | 1.85M |
| CurrentAccruedExpenses | 1.08M | 1.06M | 955.08K | 303.80K |
| InterestPayable | 107.17K | 0.00 | ||
| Payables | 482.32K | 656.45K | 1.28M | 1.55M |
| AccountsPayable | 482.32K | 656.45K | 1.28M | 1.55M |
| TotalAssets | 9.93M | 8.22M | 13.71M | 21.30M |
| TotalNonCurrentAssets | 102.61K | 151.90K | 290.75K | 290.83K |
| OtherNonCurrentAssets | 10.40K | 10.46K | 6.04K | 6.12K |
| InvestmentsAndAdvances | 0.00 | 284.71K | 284.71K | |
| LongTermEquityInvestment | 0.00 | 284.71K | 284.71K | |
| NetPPE | 92.21K | 141.44K | 0.00 | |
| GrossPPE | 92.21K | 141.44K | 0.00 | |
| OtherProperties | 92.21K | 141.44K | ||
| CurrentAssets | 9.83M | 8.07M | 13.42M | 21.01M |
| OtherCurrentAssets | 303.07K | 327.77K | 375.83K | |
| PrepaidAssets | 327.77K | 392.24K | 375.83K | |
| Receivables | 261.27K | 476.24K | 388.29K | 372.21K |
| OtherReceivables | 63.03K | 55.54K | 214.53K | 176.66K |
| AccruedInterestReceivable | 24.25K | 10.08K | 58.28K | 94.38K |
| AccountsReceivable | 173.99K | 410.62K | 115.47K | 101.17K |
| CashCashEquivalentsAndShortTermInvestments | 9.26M | 7.26M | 12.64M | 20.26M |
| OtherShortTermInvestments | 2.76M | 748.29K | 6.85M | 4.51M |
| CashAndCashEquivalents | 6.51M | 6.52M | 5.79M | 15.75M |
| CashEquivalents | 5.58M | 6.49M | 5.77M | 14.37M |
| CashFinancial | 926.29K | 25.77K | 26.78K | 1.38M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -3.97M | -6.73M | -8.08M | -11.28M |
| IssuanceOfDebt | 5.82M | 0.00 | ||
| InterestPaidSupplementalData | 257.78K | 0.00 | ||
| EndCashPosition | 6.51M | 6.52M | 5.79M | 15.75M |
| BeginningCashPosition | 6.52M | 5.79M | 15.75M | 20.64M |
| EffectOfExchangeRateChanges | -5.80K | -2.38K | -44.74K | -63.26K |
| ChangesInCash | -2.48K | 723.14K | -9.91M | -4.83M |
| FinancingCashFlow | 5.85M | 0.00 | 543.59K | 1.23M |
| CashFlowFromContinuingFinancingActivities | 5.85M | 0.00 | 543.59K | 1.23M |
| ProceedsFromStockOptionExercised | 24.25K | 0.00 | 543.59K | 1.23M |
| NetIssuancePaymentsOfDebt | 5.82M | 0.00 | ||
| NetLongTermDebtIssuance | 5.82M | 0.00 | ||
| LongTermDebtIssuance | 5.82M | 0.00 | ||
| InvestingCashFlow | -1.88M | 7.45M | -2.37M | 5.22M |
| CashFlowFromContinuingInvestingActivities | -1.88M | 7.45M | -2.37M | 5.22M |
| NetInvestmentPurchaseAndSale | -1.88M | 7.45M | -2.37M | 5.22M |
| SaleOfInvestment | 5.47M | 10.45M | 7.50M | 16.51M |
| PurchaseOfInvestment | -7.34M | -3.00M | -9.87M | -11.28M |
| OperatingCashFlow | -3.97M | -6.73M | -8.08M | -11.28M |
| CashFlowFromContinuingOperatingActivities | -3.97M | -6.73M | -8.08M | -11.28M |
| ChangeInWorkingCapital | 754.53K | -143.21K | -321.17K | 1.19M |
| ChangeInOtherWorkingCapital | 344.87K | 91.92K | -257.46K | 528.13K |
| ChangeInPayablesAndAccruedExpense | 179.66K | -206.90K | -2.61K | 769.39K |
| ChangeInAccruedExpense | 359.84K | 444.27K | 245.52K | 219.82K |
| ChangeInInterestPayable | 107.17K | 0.00 | ||
| ChangeInPayable | -180.18K | -651.17K | -248.13K | 549.56K |
| ChangeInAccountPayable | -180.18K | -651.17K | -248.13K | 549.56K |
| ChangeInPrepaidAssets | 24.74K | 64.90K | -13.93K | -95.37K |
| ChangeInReceivables | 205.26K | -93.13K | -47.17K | -13.92K |
| ChangesInAccountReceivables | 219.43K | -141.33K | -83.27K | -31.79K |
| OtherNonCashItems | 63.02K | |||
| StockBasedCompensation | 1.13M | 1.24M | 1.89M | 1.78M |
| AmortizationOfSecurities | -71.06K | -53.03K | 33.79K | 329.61K |
| OperatingGainsLosses | -38.42K | -979.17K | 49.92K | -1.51M |
| EarningsLossesFromEquityInvestments | 0.00 | -1.61M | ||
| GainLossOnInvestmentSecurities | -1.61M | |||
| NetForeignCurrencyExchangeGainLoss | 22.56K | 38.42K | 49.92K | 96.89K |
| GainLossOnSaleOfBusiness | -60.98K | -1.02M | 0.00 | |
| NetIncomeFromContinuingOperations | -5.81M | -6.80M | -9.74M | -13.07M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for DYAI
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|